Mellgard, G., Saffran, N., Chakrani, Z., McCroskery, S., Taylor, N., Patel, M., Liaw, B., Galsky, M., Oh, W., Tsao, C.-K., & Patel, V. (2024). Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy. American Journal of Clinical Oncology, 47(10), 459–464. https://doi.org/10.1097/coc.0000000000001115

Chakrani, Z., Mellgard, G., Saffran, N., McCroskery, S., Taylor, N., Patel, M., Liaw, B., Galsky, M., Oh, W. K., Tsao, C.-K., & Patel, V. G. (2024). Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted Therapy. American Journal of Clinical Oncology, 47(6), 271–278. https://doi.org/10.1097/coc.0000000000001087

Kharofa, J. R., Yothers, G., Kachnic, L. A., Ajani, J., Meyer, J. E., Augspurger, M. E., Okawara, G. S., Garg, M. K., Schefter, T. E., Swanson, T. A., Doncals, D. E., Kim, H., Zaki, B. I., Narayan, S., Lee, R. J., Mamon, H. J., Schwartz, M. A., Moughan, J., & Crane, C. H. (2022). Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials. American Journal of Clinical Oncology, 45(12), 534–536. https://doi.org/10.1097/coc.0000000000000955

Witek, M. E., Kimple, R. J., Avey, G. D., Burr, A. R., Chandereng, T., Yu, M., Hu, R., Wieland, A. M., Labby, Z. E., Bruce, J. Y., Brower, J. V., Hartig, G. K., & Harari, P. M. (2022). Prospective Study of PET/MRI Tumor Response During Chemoradiotherapy for Patients With Low-risk and Intermediate-risk p16-positive Oropharynx Cancer. American Journal of Clinical Oncology, 45(5), 202–207. https://doi.org/10.1097/coc.0000000000000910